Use the hyperlinks, where available to access additional clinical trial information.
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Hutchison Medipharma Limited
This trial will have a dose escalation phase and a dose expansion phase. Patients eligible for participation in the dose escalation phase will receive a specified dose of HMPL-523 daily for a 28 day cycle. Patients eligible for participation in the dose expansion phase will receive the highest tolerated dose in continuous 28 day cycles.